NVAX
Price
$7.56
Change
+$0.09 (+1.20%)
Updated
Sep 2, 04:34 PM (EDT)
Capitalization
1.21B
64 days until earnings call
OPK
Price
$1.38
Change
-$0.00 (-0.00%)
Updated
Sep 2, 04:34 PM (EDT)
Capitalization
1.1B
64 days until earnings call
Interact to see
Advertisement

NVAX vs OPK

Header iconNVAX vs OPK Comparison
Open Charts NVAX vs OPKBanner chart's image
Novavax
Price$7.56
Change+$0.09 (+1.20%)
Volume$1.51K
Capitalization1.21B
OPKO Health
Price$1.38
Change-$0.00 (-0.00%)
Volume$4.92K
Capitalization1.1B
NVAX vs OPK Comparison Chart in %
Loading...
NVAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OPK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Regeneron Pharmaceuticals (NASDAQ:REGN), IQVIA Holdings (NYSE:IQV), Biogen (NASDAQ:BIIB), Incyte Corp (NASDAQ:INCY), Illumina (NASDAQ:ILMN), Exelixis (NASDAQ:EXEL), Moderna (NASDAQ:MRNA), Exact Sciences Corp (NASDAQ:EXAS).

Industry description

Few industries pique investor interest like the high-risk, high-reward biotechnology sector. It is not unusual for a biotech company’s stock to soar in value following the development of a successful product...even if it is just as likely that tens of millions of dollars in research will lead to nothing substantial. Biotech companies earn headlines for developing lifesaving and (potentially) massively lucrative treatments for illness, but the industry’s scope extends beyond healthcare to food and agriculture, industrial processing, and more. Any company producing technology that incorporates biological organisms falls within the sector. The search for the next big thing in biotech may come with risk, but investors have reason for optimism. Biotech products like DNA sequencing and gene therapy are experiencing increased demand and decreasing prices, while rising populations around the world mean demand for food and agricultural products resistant to environmental factors. Biotech’s biggest names include multinational corporations like Johnson & Johnson, Amgen, and Roche, who each sport market capitalizations in the hundreds of billions of dollars. With new government rules opening China as a market for new treatments, the biotech sector holds significant growth potential – and corresponding profitability for investors.

Market Cap

The average market capitalization across the biotechnology Theme is 6.85B. The market cap for tickers in the group ranges from 658 to 186.06B. TMO holds the highest valuation in this group at 186.06B. The lowest valued company is MTEM at 658.

High and low price notable news

The average weekly price growth across all stocks in the biotechnology Theme was 2%. For the same Theme, the average monthly price growth was 14%, and the average quarterly price growth was 42%. NBY experienced the highest price growth at 96%, while OTLK experienced the biggest fall at -68%.

Volume

The average weekly volume growth across all stocks in the biotechnology Theme was -7%. For the same stocks of the Theme, the average monthly volume growth was -38% and the average quarterly volume growth was -32%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 59
P/E Growth Rating: 76
Price Growth Rating: 54
SMR Rating: 87
Profit Risk Rating: 90
Seasonality Score: -26 (-100 ... +100)

Notable companies

The most notable companies in this group are Novavax (NASDAQ:NVAX).

Market Cap

The average market capitalization across the group is 1.15B. The market cap for tickers in the group ranges from 1.1B to 1.21B. NVAX holds the highest valuation in this group at 1.21B. The lowest valued company is OPK at 1.1B.

High and low price notable news

The average weekly price growth across all stocks in the group was -3%. For the same group, the average monthly price growth was 6%, and the average quarterly price growth was -16%. OPK experienced the highest price growth at -2%, while NVAX experienced the biggest fall at -5%.

Volume

The average weekly volume growth across all stocks in the group was -40%. For the same stocks of the group, the average monthly volume growth was 18% and the average quarterly volume growth was -65%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 68
P/E Growth Rating: 56
Price Growth Rating: 60
SMR Rating: 97
Profit Risk Rating: 100
Seasonality Score: -5 (-100 ... +100)
VS
NVAX vs. OPK commentary
Sep 02, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NVAX is a Buy and OPK is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 02, 2025
Stock price -- (NVAX: $7.47 vs. OPK: $1.38)
Brand notoriety: NVAX: Notable vs. OPK: Not notable
NVAX represents the Biotechnology, while OPK is part of the Medical Specialties industry
Current volume relative to the 65-day Moving Average: NVAX: 93% vs. OPK: 64%
Market capitalization -- NVAX: $1.21B vs. OPK: $1.1B
NVAX [@Biotechnology] is valued at $1.21B. OPK’s [@Medical Specialties] market capitalization is $1.1B. The market cap for tickers in the [@Biotechnology] industry ranges from $100.25B to $0. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Biotechnology] industry is $1.85B. The average market capitalization across the [@Medical Specialties] industry is $10.68B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NVAX’s FA Score shows that 1 FA rating(s) are green whileOPK’s FA Score has 0 green FA rating(s).

  • NVAX’s FA Score: 1 green, 4 red.
  • OPK’s FA Score: 0 green, 5 red.
According to our system of comparison, NVAX is a better buy in the long-term than OPK.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NVAX’s TA Score shows that 4 TA indicator(s) are bullish while OPK’s TA Score has 8 bullish TA indicator(s).

  • NVAX’s TA Score: 4 bullish, 5 bearish.
  • OPK’s TA Score: 8 bullish, 1 bearish.
According to our system of comparison, OPK is a better buy in the short-term than NVAX.

Price Growth

NVAX (@Biotechnology) experienced а -4.72% price change this week, while OPK (@Medical Specialties) price change was -2.13% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.65%. For the same industry, the average monthly price growth was +22.42%, and the average quarterly price growth was +32.93%.

The average weekly price growth across all stocks in the @Medical Specialties industry was +0.14%. For the same industry, the average monthly price growth was +9.67%, and the average quarterly price growth was +9.39%.

Reported Earning Dates

NVAX is expected to report earnings on Nov 05, 2025.

OPK is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+6.65% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

@Medical Specialties (+0.14% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NVAX($1.21B) has a higher market cap than OPK($1.1B). OPK YTD gains are higher at: -6.122 vs. NVAX (-7.090). NVAX has higher annual earnings (EBITDA): 496M vs. OPK (59.6M). NVAX has more cash in the bank: 612M vs. OPK (272M). NVAX has less debt than OPK: NVAX (228M) vs OPK (396M). NVAX has higher revenues than OPK: NVAX (1.08B) vs OPK (664M).
NVAXOPKNVAX / OPK
Capitalization1.21B1.1B111%
EBITDA496M59.6M832%
Gain YTD-7.090-6.122116%
P/E Ratio3.36N/A-
Revenue1.08B664M163%
Total Cash612M272M225%
Total Debt228M396M58%
FUNDAMENTALS RATINGS
NVAX vs OPK: Fundamental Ratings
NVAX
OPK
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
81
Overvalued
55
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10094
PRICE GROWTH RATING
1..100
6061
P/E GROWTH RATING
1..100
1498
SEASONALITY SCORE
1..100
10n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

OPK's Valuation (55) in the Biotechnology industry is in the same range as NVAX (81). This means that OPK’s stock grew similarly to NVAX’s over the last 12 months.

OPK's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as NVAX (100). This means that OPK’s stock grew similarly to NVAX’s over the last 12 months.

OPK's SMR Rating (94) in the Biotechnology industry is in the same range as NVAX (100). This means that OPK’s stock grew similarly to NVAX’s over the last 12 months.

NVAX's Price Growth Rating (60) in the Biotechnology industry is in the same range as OPK (61). This means that NVAX’s stock grew similarly to OPK’s over the last 12 months.

NVAX's P/E Growth Rating (14) in the Biotechnology industry is significantly better than the same rating for OPK (98). This means that NVAX’s stock grew significantly faster than OPK’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NVAXOPK
RSI
ODDS (%)
Bearish Trend 5 days ago
90%
Bullish Trend 5 days ago
74%
Stochastic
ODDS (%)
Bullish Trend 5 days ago
85%
Bearish Trend 5 days ago
86%
Momentum
ODDS (%)
Bearish Trend 5 days ago
88%
Bullish Trend 5 days ago
78%
MACD
ODDS (%)
Bearish Trend 5 days ago
88%
Bullish Trend 5 days ago
75%
TrendWeek
ODDS (%)
Bearish Trend 5 days ago
89%
Bearish Trend 5 days ago
80%
TrendMonth
ODDS (%)
Bullish Trend 5 days ago
83%
Bullish Trend 5 days ago
73%
Advances
ODDS (%)
Bullish Trend 16 days ago
84%
Bullish Trend 16 days ago
75%
Declines
ODDS (%)
Bearish Trend 8 days ago
89%
N/A
BollingerBands
ODDS (%)
Bearish Trend 5 days ago
90%
Bullish Trend 5 days ago
74%
Aroon
ODDS (%)
Bullish Trend 5 days ago
85%
Bullish Trend 5 days ago
73%
View a ticker or compare two or three
Interact to see
Advertisement
NVAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OPK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MYICX9.26-0.02
-0.22%
NYLI WMC International Research Eq Cl C
SNWIX69.28-0.24
-0.35%
Easterly Snow Small Cap Value I
TSMGX16.04-0.07
-0.43%
Touchstone Sands Cptl Emerg Mkts Gr A
HDVFX14.89-0.08
-0.53%
Hartford International Equity F
TQAIX46.26-0.45
-0.96%
T. Rowe Price Integrated US Sm Gr Eq I

NVAX and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, NVAX has been loosely correlated with MRNA. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if NVAX jumps, then MRNA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVAX
1D Price
Change %
NVAX100%
-1.45%
MRNA - NVAX
48%
Loosely correlated
-1.55%
BNTX - NVAX
43%
Loosely correlated
-1.89%
THRD - NVAX
42%
Loosely correlated
N/A
ARCT - NVAX
40%
Loosely correlated
-1.68%
XNCR - NVAX
37%
Loosely correlated
+0.99%
More

OPK and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, OPK has been loosely correlated with ICUI. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if OPK jumps, then ICUI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OPK
1D Price
Change %
OPK100%
-2.82%
ICUI - OPK
41%
Loosely correlated
+0.49%
CLPT - OPK
39%
Loosely correlated
N/A
UTMD - OPK
36%
Loosely correlated
+0.24%
XAIR - OPK
35%
Loosely correlated
+1.83%
NOTV - OPK
34%
Loosely correlated
+0.60%
More